All the Active Ingredient Drugs
Tyrosine Kinase Inhibitor. Ruxolitinib Phosphate 5 mg, 10 mg, 15 mg, 20 mg. TAB: blist.: 56, bottle.: 60×5, 15, 20mg
MF: The recomm. start. dose: in is 15
mg ×2/d for pts. with a plat. count
between 100,000/mm³ and 200,000/
mm 3 and 20 mg ×2/d for pts. with a
plat. count of >200,000/mm³.
PV: The recomm. start. dose of is 10
Limited inform. to recommend a start.
dose for pts. with plat. count. between
50,000/mm³ & <100,000/mm³.
The max. recomm. start. dose in these
pts. is 5 mg ×2/d and the pts. should be
Dose modific.: Doses may be titrat. based on safety & efficacy. Tmt. should be discont. for plat. counts less than 50,000/mm³ or absolute neutrophil counts less than 500/mm³. In PV, tmt. should also be interrupt. when haemoglobin is below
8 g/dl. After recov. of blood count. above these levels, dosing may be re-started at 5 mg ×2/d and gradual. incr. based on careful. See. lit.
Myelofibrosis (MF).: Tmt. of dis.-related splenomeg.or sympt. in adult pts. with prim. MF (also known as chron. idiopath. MF), post polycythaem. vera myelofibrosis or post essential thrombocythaem. MF.
Polycythaem. vera (PV).: Tmt. of adult pts. with PV who are resist. to or intolerant of hydroxyurea.
C/I: Hypersens. Preg. Lact.